Long-Lasting Effectiveness of Intravenous Immunoglobulin in a Patient with Inclusion-Body Myositis
Authors: Beejadi N. Mukunda, P. Dileep Kumar, Howard R. Smith
Journal: Annals of Internal Medicine (2001)

Letters19 June 2001Long-Lasting Effectiveness of Intravenous Immunoglobulin in a Patient with Inclusion-Body MyositisBeejadi N. Mukunda, MD, P. Dileep Kumar, MD, and Howard R. Smith, MDBeejadi N. Mukunda, MDHuron Hospital/Cleveland Clinic Health System; Cleveland, OH 44112 (Mukunda, Dileep Kumar, Smith)Search for more papers by this author, P. Dileep Kumar, MDHuron Hospital/Cleveland Clinic Health System; Cleveland, OH 44112 (Mukunda, Dileep Kumar, Smith)Search for more papers by this author, and Howard R. Smith, MDHuron Hospital/Cleveland Clinic Health System; Cleveland, OH 44112 (Mukunda, Dileep Kumar, Smith)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-134-12-200106190-00031 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:Inclusion-body myositis is characterized by various degrees of endomysial inflammation, atrophic fibers, eosinophilic cytoplasmic inclusions, and characteristic rimmed vacuoles with filamentous inclusions (1). Slowly progressing weakness and atrophy are seen in both proximal and distal muscle groups. The disease has a poor prognosis. We describe a patient with inclusion-body myositis who improved with a course of intravenous immunoglobulin.Inclusion-body myositis was diagnosed in a 63-year-old woman in 1995. She had difficulty walking and getting up and had wasting of the legs. She was treated with prednisone and then azathioprine, without benefit. Weakness progressed, and she became wheelchair ...References1. Soueidan SA, Dalakas MC. Treatment of inclusion-body myositis with high-dose intravenous immunoglobulin. Neurology. 1993;43:876-9. [PMID: 8492940] CrossrefMedlineGoogle Scholar2. Leff RL, Miller FW, Hicks J, Fraser DD, Plotz PH. The treatment of inclusion body myositis: a retrospective review and a randomized, prospective trial of immunosuppressive therapy. Medicine Baltimore. 1993;72:225-35. [PMID: 8393509] CrossrefMedlineGoogle Scholar3. Calabrese LH, Chou SM. Inclusion body myositis. Rheum Dis Clin North Am. 1994;20:955-72. [PMID: 7855331] CrossrefMedlineGoogle Scholar4. Calabrese LH, Mitsumoto H, Chou SM. Inclusion body myositis presenting as treatment-resistant polymyositis. Arthritis Rheum. 1987;30:397-403. [PMID: 3034295] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: Huron Hospital/Cleveland Clinic Health System; Cleveland, OH 44112 (Mukunda, Dileep Kumar, Smith) PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byCritical review of the role of intravenous immunoglobulins in idiopathic inflammatory myopathiesTreatment of inclusion body myositis: is low-dose intravenous immunoglobulin the solution?Consensus statement: The use of intravenous immunoglobulin in the treatment of neuromuscular conditions report of the aanem AD HOC committeeInclusion body myositisIntravenous Immunoglobulin Use for Neurologic Diseasesi.v.-Immunglobuline bei chronischen idiopathischen MyositidenInflammatory myopathies: Clinical, diagnostic and therapeutic aspectsSporadic Inclusion Body Myositis and Hereditary Inclusion Body Myopathy 19 June 2001Volume 134, Issue 12Page: 1156KeywordsIntravenous immunoglobulinMethotrexateMusclesMyositisNatural killer cellsPatientsPolymyositisT cellsWalkingWheelchairs ePublished: 19 June 2001 Issue Published: 19 June 2001 Copyright & PermissionsCopyright © 2001 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...